focus -WSS

focus

author：focus 2025-10-01 00:16:49 - browse：21

Illumina, the leading maker of DNA sequencing machines, said Sunday that it would divest Grail, the developer of a multi-cancer screening test, which it bought over the objections of regulators in the U.S. and Europe in August 2021.

Illumina said the decision to spin Grail off followed a Friday decision of the U.S. Fifth Circuit Court of Appeals, which held that the merger was anti-competitive. It said that it would divest Grail either by selling it to another company or listing it on capital markets, consistent with an order from the European Commission, and that it aims to finalize the terms of the deal by the end of the second quarter of 2024.

The decision opens what should be the final chapter in one of the most disastrous attempted mergers in biotech history. Illumina, a storied name that had delivered investors strong returns over two decades, spun out Grail in 2016 in order to raise money to fund the company’s work. Then, it announced plans to re-acquire the firm for $7.1 billion in Sept. 2020.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： NIH director takes cautious approach to Biden drug pricing priority

explore

WSS

Francis Collins on trust in science and how Covid communications failed

23andMe had bad news about my health. I wish a person had delivered it

State Dept. review finds Biden bears some blame for Afghanistan failures

After affirmative action ruling, medical educators look to 'holistic review'

Jerome Adams on the need for new antivirals for Covid

Virginia high school admissions case could be legal follow

leisure time

focus

hotspot

New air purifier tech could be key to improving indoor air quality

Walensky prepares to leave CDC — and Congress — behind

In age of alternative facts, a scholarly course on calling out crap

Why doctors need education on FDA device approval process

Supreme Court strikes down use of affirmative action

Eli Lilly, Pfizer, and others want in on the online prescription market

Wildfire smoke exposes gaps in outdoor worker protections

Prior authorization will have to move faster under new Biden rule

Dobbs anniversary: the lost opportunity of abortion as health care

After affirmative action ruling, medical educators look to 'holistic review'

leisure time

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

AI generated plenty of interest at JPM but not a lot of trust

Peter Hotez and the public health issue of online harassment

Research misconduct: Proposed new rules face resistance

Copay coupons to count toward deductibles, after Biden court move

EU regulator recommends expanding Mounjaro approval to obesity

leisure time

explore

focus

entertainment